Skip to content

Advance Agrolife Limited (ADVANCE)

Small Cap

Pharma stocks · Small cap · NSE

Advance Agrolife Limited operates in Agrochemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹158.08
-0.35 · -0.22%
Market cap ₹743 Cr
Data qualityFresh enough for analysisQuote updated 18 Oct, 05:45 pm IST
Details
Quote18 Oct, 05:45 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result06 Aug, 06:14 pm IST
Score19 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens

Trend score and candlestick chart

86Strong Bull

full bull SMA stack · SMA20 +6.5% / mo · RSI overbought · MACD + · near 52W high · sector +3.7pp vs Nifty 500 (3M)

Stock trend: 78
Sector RS: 98
Sector 3M: -2.0% vs Nifty 500 -5.7%

FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence

Technical chart

ADVANCEW candles · FIT view+43.4%
Latest close ₹158.08 on 2026-10-12
Bar
+39.9%
RSI
70
MACD hist
3.05
52W pos
92%
Visible chart range
Candle interval
2026-10-12O ₹113.01H ₹164.30L ₹113.01C ₹158.08Vol 3.5Cr sh
₹80.09₹102.14₹124.20₹146.25₹168.3152H52L₹158.082025-092025-122026-032026-06VolRSIMACD2025-102026-012026-042026-082026-11
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

ADVANCENifty PharmaNifty 500
-11%+6%+24%+41%16 Jul31 Aug16 Oct16 Oct 2026ADVANCE +36.7%Nifty Pharma -1.0%Nifty 500 -4.2%
ADVANCE
+36.7%
Nifty 500
-4.2%
Nifty Pharma
-1.0%
Vs Nifty 500
+40.8 pp
Chart stats
16 Oct 2026
From 52W high
-3.8%
₹164.3
52W range position
92%
₹84.1 - ₹164.3
ATR (14)
5.4%
₹8.5
Volume vs 20D
0.80x
Latest completed session
Avg traded value
₹28.1 Cr
20-session average
20D price channel
₹106.5 - ₹164.3
76.6% annualized volatility
Research snapshot

What the evidence says now

Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.

Weak U-Score but strong trend: momentum may be ahead of fundamentals.

Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST
40

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Latest result
Excellent
100

Revenue +95.3% · PAT +155.6% YoY

Technical
Strong Bull
86

Price trend and sector-relative-strength timing.

Valuation
Legacy model
-153.9%

Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.

Trust
Limited evidence
72

Financial-only signal; management claim evidence is not sufficient yet.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Latest result

Quarter ended 30 Jun 2026

Excellent · 100/100

Rev +95% YoY · PAT +156% YoY · margin expansion · +166% QoQ · operating leverage

Filed 06 Aug 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹330 Cr+95.3%+166.1%
EBITDA₹35 Cr+105.9%+169.2%
Operating margin11.0%+100 bps+0 bps
PAT₹23 Cr+155.6%+228.6%
PAT margin7.0%+164 bps+132 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E
29.00
P/B
—
EV/EBITDA
14.44
Market Cap
743.00Cr

Profitability

ROE
29.10%
ROCE
28.00%
ROA
7.41%
Dividend Y
—

Growth (CAGR)

Revenue 5Y
9.98%
EPS 5Y
4.00%
Revenue 3Y
9.98%
EPS 3Y
4.00%

Balance Sheet

Debt/Equity
0.79
Interest Coverage
7.00×
Altman Z
3.98
Book Value
—

Cash Flow

FCF Yield
—
FCF Positive Y
0/5
OCF
6.00 Cr
EPS TTM
5.70

Shareholding

Promoter Hold
69.89%
Promoter Pledge
0.00%
Momentum 52W
46%

Financial History

Updated 19/10/2026

Revenue

₹ Cr
Latest: 330+166.1% vs prev
0330.0Jun 2024: 132Sep 2024: 167Dec 2024: 113Mar 2025: 90.0Jun 2025: 169Sep 2025: 213Dec 2025: 133Mar 2026: 124Jun 2026: 330Q1 24Q2 24Q3 24FY25Q1 25Q2 25Q3 25FY26Q1 26

Net Profit

₹ Cr
Latest: 23.0+228.6% vs prev
023.0Jun 2024: 7.0Sep 2024: 14.0Dec 2024: 3.0Mar 2025: 1.0Jun 2025: 9.0Sep 2025: 16.0Dec 2025: 3.0Mar 2026: 7.0Jun 2026: 23.0Q1 24Q2 24Q3 24FY25Q1 25Q2 25Q3 25FY26Q1 26
ROE is shown only in the Annual view — quarterly equity data isn't published.

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Weekly technical trend read

Bullish setup

Trend is constructive — long-term trend unclear. RSI 70.

  • SMA20 rising (~3.8% over last month) — short-term momentum positive.
  • RSI(14) at 70 — rising, no extreme reading.
  • MACD above signal, histogram expanding — bullish momentum building.
  • 4% off 52W high · 88% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

81
RS percentile
Stage 2 UptrendNew S2
1M return
+41.6%
3M return
+39.1%
6M return
+39.4%
1Y return
+10.9%
RS 1D
-1
RS 20D
+9
Sector rank
#1
Industry rank
-
Stage evidence
  • Price is 42.2% above the 30-week proxy.
  • The 50-DMA is above the 30-week proxy and its slope is rising +1.2%.
  • Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
15 Oct 2026
S2 age
2 trading sessions
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
254 observations
16 Oct 2026Value 151.47-0.62%
85103120138156Oct 25Feb 26Jun 26Oct 26151
RS vs Nifty 500151

Valuation & peers

U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies

40U-SCORE
Premium Compounder

Fundamental score breakdown

U band · WATCHLIST
Valuation3/30
Growth6/25
Quality17/20
Balance Sheet8/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
40

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

40/100 · legacy band WATCHLIST

Positive drivers

  • Piotroski is strong at 8/9.
  • Quality contributes 17/20 to the score.
  • Balance sheet contributes 8/15 to the score.

Main drags

  • Fair-value margin of safety is negative at -153.9%.
  • Valuation is weaker at 3/30; verify the latest quarterly trend.
  • Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
29.0
PB
—
EV/EBITDA
14.4
ROE
29.1%
ROCE
28.0%
FCF Yield
—
Debt/Equity
0.8
MoS
-153.9%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 19 Oct 2026
v4.3-runtime-valuation
Final score
40
Previous: 40
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-153.9%
Previous: -153.9%

Score history

12 stored score snapshots. Latest stored move: +0 points.

19 Oct 2026
v4.3-runtime-valuation
41
41
41
41
41
41
40
40
40
40
40
40

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
—
Growth-justified P/E
10.9
Growth-justified Value
₹62.24
-153.9% MoS
PEG
7.25

Comparable companies

Peers

Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
BESTAGRO
Small
Best Agrolife Limited
Agrochemicals
match 170
31
21.2
1.1%
-949%
OVERVALUED
CLSL
SME
Crop Life Science Ltd.
Agrochemicals
match 157
35
16.8
8.1%
+63%
WATCHLIST
DHARMAJ
Small
Dharmaj Crop Guard Limited
Agrochemicals
match 147
48
15.0
13.3%
+65%
FAIR VALUE
HERANBA
Small
Heranba Industries Limited
Agrochemicals
match 147
16
—
-9.7%
—
OVERVALUED
EXCELINDUS
Small
Excel Industries Limited
Agrochemicals
match 144
46
16.1
4.6%
-85%
FAIR VALUE

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Advance Agrolife Limited operates in Agrochemicals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score
72Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 69th percentile of the scored universe and 58th percentile within Pharma. Main check: cash conversion is weak at 43/100.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026
management-trust-v1
8 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank
69th percentile

overall median 67 · Pharma: 58th pctile, median 70 · Small: 71st pctile, median 66

Evidence depth
Financial-only

8 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
82
strong · capital discipline
Results
79
strong · quarterly consistency

Trust positives

  • ▸Promoter holding is 69.9%.
  • ▸Promoter pledge is zero.
  • ▸ROCE is 28%.
  • ▸4/4 latest quarters had positive YoY revenue growth.

Trust risks

  • ▸Only 0 years of positive FCF.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

12 shown
AnnouncementSep 2026

Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Directorate 18 Sep - 24th AGM held on September 18, 2026; shareholders approved director appointments, redesignation, remuneration revisions, and related-party transactions.

Source: Bse

Open source ↗
AnnouncementSep 2026

Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 29 Aug - Advance Agrolife to hold one-on-one virtual investor meeting with Equirus Capital on September 1, 2026.

Source: Bse

Open source ↗
Investor presentationAug 2026

Aug 2026 · PPT

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Aug - Newspaper Advertisement - Notice of 24th Annual General Meeting and E-Voting Information

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Aug - Newspaper Advertisement - Information Regarding 24th Annual General Meeting of the Company

Source: Bse

Open source ↗
AnnouncementJun 2026

Jun 2026 · Announcement under Regulation 30 (LODR)-Monitoring Agency Report 6 Aug - CARE report for June 30, 2026 shows IPO proceeds fully utilized with no deviation.

Source: Bse

Open source ↗
AnnouncementJun 2026

Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug - Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026

Source: Bse

Open source ↗
AnnouncementJun 2026

Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Aug - Advance Agrolife reported Q1 FY27 revenue ₹3,304 million, PAT ₹225.5 million, and began Unit-5 construction.

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Jun - Intimation of Schedule of Investors / Analysts meet "Choice Institutional Equities - Insight X 2026"

Source: Bse

Open source ↗
Investor presentationMay 2026

May 2026 · PPT

Source: Bse

Open source ↗
Investor presentationMay 2026

May 2026 · PPT

Source: Bse

Open source ↗
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.